Research programme: adenosine A2A receptor antagonists - Advinus Therapeutics

Drug Profile

Research programme: adenosine A2A receptor antagonists - Advinus Therapeutics

Alternative Names: Ado A-2A receptor antagonist - Advinus; Ado A2AR antagonist - Advinus

Latest Information Update: 02 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advinus Therapeutics
  • Class Antiparkinsonians; Neuroprotectants
  • Mechanism of Action Adenosine A2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Parkinson's disease

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 21 Jan 2016 Preclinical trials in Parkinson's disease in India (unspecified route)
  • 20 Jan 2016 Adenosine A2A receptor antagonist - Advinus Therapeutics is available for licensing as of 20 Jan 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top